Annual report pursuant to Section 13 and 15(d)

Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative)

v3.24.1
Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Apr. 08, 2022
Nov. 19, 2021
Nov. 19, 2020
Dec. 12, 2019
Dec. 31, 2023
Dec. 31, 2022
Therapeutics development award         $ 1,096 $ 3,188
Other Liabilities [1]         88
License Agreement Terms [Member]            
License agreement description         The Second Amended and Restated Exclusive License Agreement provides for, among other things, the payment of (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $100 when and if sales of products using the licensed technology reach the specified sales threshold and (3) an annual license fee of $50 over the term of the License Agreement. The term of the License Agreement will remain in effect until the expiration of the last-to-expire patent rights licensed or seven and one-half years from the date of the first commercial sale of a licensed product under this agreement, whichever is later.  
Cystic Fibrosis Foundation Therapeutics Development Award [Member]            
Other Liabilities           88
Research and development, costs incurred         $ 88 811
BioNTech Agreement [Member]            
Revenue recognized $ 2,750         688
CFF Agreement [Member]            
Grants receivable         3,635  
Additional milestone payment         4,555  
CFF Agreement [Member] | Accrued Liabilities [Member]            
Other Liabilities         0 88
CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | Cystic Fibrosis Foundation Therapeutics Development Award [Member]            
Therapeutics development award     $ 4,234      
Previously received awards     $ 484      
Additional milestone payment   $ 321        
Genentech Feasibility Study Agreement [Member]            
Revenue recognized       $ 33 $ 33 $ 0
Genentech Feasibility Study Agreement [Member] | Three Molecules [Member]            
Revenue recognized       $ 100    
[1] At December 31, 2022, the balance of $88 was related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements, and Other Research and Development Agreements).